Accès ouvert
2026
article
OpenAlex
Karnav Modi, Himil Mahadevia, Raj Shah, Deepthi Vodnala et autres
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed or refractory hematologic malignancies. However, real-world data describing cardiovascular complications with CAR T-cell therapy remain limited. METHODS: Using the National Inpatient Sample, we identified hospitalizations involving CAR T-cell therapy …
us
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Arshi Syal, Yajur Arya, Oluwatayo Adeoye, Himil Mahadevia et autres
712 Background: Bladder cancer is one of the most common malignancies of the urinary tract. Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the treatment of type 2 diabetes and obesity. Their pleiotropic benefits including improved insulin sensitivity, potential anti-proliferative and …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Yajur Arya, Arshi Syal, Oluwatayo Adeoye, Himil Mahadevia et autres
484 Background: Renal cell carcinoma (RCC) is the most common type of urogenital cancer. Lifestyle and metabolic risk factors seem to play an important role in this rising incidence. Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the treatment of type …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
A. Syal, Yajur Arya, C. Jones, Himil Mahadevia et autres
Abstract Introduction: Patients with metastatic breast cancer frequently develop bone metastases and experience other skeletal-related events (SREs). These complications substantially impair quality of life and may negatively influence clinical outcomes. In this context, bisphosphonates and denosumab are the most commonly utilized therapeutic …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Yajur Arya, A. Syal, C. Jones, Himil Mahadevia et autres
Abstract Introduction: Breast cancer most commonly metastasizes to the bones, with bone pain and other skeletal related events (SREs) having a limiting effect on quality of life. Bisphosphonates are widely used in breast cancer patients to reduce SREs and bone loss, particularly …
us
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Nitya Batra, Mahnoor Sukaina, Yagnapriya Ammakola, Rahul Mishra et autres
402 Background: Trastuzumab deruxtecan (T-DXd) is a HER2-targeted antibody-drug conjugate (ADC) with a cytotoxic payload. TDXd was approved in 2021 to be used in advanced gastric or GEJ cancers. Although given the recent approval, real-world evidence on efficacy and safety is limited. …
us, pk
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Yajur Arya, Arshi Syal, Himil Mahadevia, Nitya Batra et autres
83 Background: Colon cancer is among the leading causes of cancer-related morbidity and mortality globally, with an increasing incidence observed in younger populations. Lifestyle and metabolic risk factors seem to play an important role in this rising incidence. Glucagon-like peptide-1 (GLP-1) receptor …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Arshi Syal, Yajur Arya, Himil Mahadevia, Nitya Batra et autres
517 Background: Hepatocellular carcinoma (HCC) is a major cause of cancer related morbidity and mortality worldwide, with increased incidence in patients with chronic liver disease, obesity and metabolic syndrome. Of note, increasing burden of metabolic dysfunction-associated steatohepatitis (MASH) and non-alcoholic fatty livery …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Abdul Wali Khan, Simran Chandra, Himil Mahadevia, Janakiraman Subramanian et autres
Immune checkpoint inhibitors (ICIs) are established treatments for various malignancies, including lung, kidney, and colorectal cancers. However, their broad use has led to an increase in immune-related adverse events (irAEs), with thyroiditis, colitis, and pneumonitis being the most common. Hemophagocytic lymphohistiocytosis (HLH) …
us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Himil Mahadevia, An‐Lin Cheng, Aakriti Adhikari, Yajur Arya et autres
Abstract Introduction: BL and DLBCL are the two most common lymphomas associated with HIV infection. Notably, clinical trials often exclude HIV-positive patients and prior retrospective studies often lacked long-term follow-up on overall survival (OS). This has limited our knowledge about the influence …
us, gb
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Arshi Syal, Yajur Arya, Angimar Uriepero, Himil Mahadevia et autres
Abstract Introduction Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the treatment of type 2 diabetes and obesity. Emerging evidence suggesting their potential anti-inflammatory and anti-proliferative effects as well as cardiovascular benefits. Chronic myeloid leukemia (CML), a myeloproliferative neoplasm, has seen …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Himil Mahadevia, Karnav Modi, Raj Shah, Shivani Modi et autres
Abstract Introduction: CAR T-cell therapy is an important treatment option for patients with relapsed or refractory (R/R) DLBCL. Three CAR T-cell products have received approval: axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi), and tisagenlecleucel (Kymriah). Although direct head-to-head studies comparing the three therapies …
us
(code pays fourni par la source)